Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Rang in Aktien #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Aktienkurs
$0.12164306
Zuletzt synchronisiert: 2024-11-11
Marktkapitalisierung
$38.53M
Veränderung (1 Tag)
-4.14%
Veränderung (1 Jahr)
0.00%
Land
AU
Handel PharmAust Limited (PAA)

Kategorie

Kursverlauf für PharmAust Limited (PAA)
Höchster Schlusskurs: $0.12 am 2024-11-01

Niedrigster Schlusskurs: $3.11 am 2001-10-01
Kursverlauf der Aktie von PharmAust Limited von 2001 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 72.79%
2023 61.50%
2022 -33.17%
2021 -20.54%
2020 20.68%
2019 171.67%
2018 -30.35%
2017 4.90%
2016 -29.98%
2015 -55.93%
2014 -33.04%
2013 25.44%
2012 -54.31%
2011 -8.75%
2010 -46.71%
2009 152.12%
2008 -65.75%
2007 -55.38%
2006 -27.70%
2005 -34.70%
2004 20.98%
2003 69.43%
2002 -28.84%
2001 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$546.39 38.55%
US
$1.03K 56.51%
NL
$120.74 -14.98%
AU
$142.97 431.68%
US
$763.17 7.23%
CH